ReviewCurrent treatment options in oncology2018
Right Versus Left Colon Cancer: Resectable and Metastatic Disease.
Review in Current treatment options in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer.Molecular diagnosis & therapy · 2026Article
- Clinicopathological Features of Right vs. Left Colorectal Carcinomas: Do the Differences Really Matter?Life (Basel, Switzerland) · 2026Article
- Could molecular variations be predictive in right and left colon cancer in different gender and age groups?PloS one · 2026Article
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Development and validation of predictive models for disease-free survival and overall survival in non-metastatic right-sided colon adenocarcinoma patients based on inflammatory and nutritional indices.BMC gastroenterology · 2025Article
- Differential response to immunotherapy in different lesions of MSI-H double primary colorectal cancer: a case report and literature review.AME case reports · 2025Article
- The Role of Tumor Location on Endoscopic and Surgical Management of Malignant Colon Polyps.Annals of surgical oncology · 2024Article
- Investigation of the correlation between AGRN expression and perineural invasion in colon cancer.Frontiers in molecular biosciences · 2024Article
- [Clinical and histopathological characteristics of malignant colon tumors by location].Revista medica del Instituto Mexicano del Seguro Social · 2023Observational
- Correlation between mismatch repair statuses and the prognosis of stage I-IV colorectal cancer.Frontiers in oncology · 2023Article
- A Novel Prognostic Index for Metastatic Colon Cancer: The Prognostic Immune Nutritional Index.Cureus · 2023Article
- Intertwined leukocyte balances in tumours and peripheral blood as robust predictors of right and left colorectal cancer survival.World journal of gastrointestinal oncology · 2022Article
- Nomogram for predicting overall survival time of patients with stage IV colorectal cancer.Gastroenterology report · 2022Article
- Review
- Construction of a long noncoding RNA-based competing endogenous RNA network and prognostic signatures of left- and right-side colon cancer.Cancer cell international · 2021Article
- Prognostic Immune-Related Analysis Based on Differentially Expressed Genes in Left- and Right-Sided Colon Adenocarcinoma.Frontiers in oncology · 2021Article
- Development and validation of prognostic nomograms for early-onset locally advanced colon cancer.Aging · 2020Article
- IL-34, IL-36 and IL-38 in colorectal cancer-key immunoregulators of carcinogenesis.Biophysical reviews · 2020Review
- IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?BMC cancer · 2020Article
- Prognostic Impact of the Number of Examined Lymph Nodes in Stage II Colorectal Adenocarcinoma: A Retrospective Study.Gastroenterology research and practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementColorectal cancer does not represent a single anatomic entity and side of origin has a key impact on prognosis and response to different systemic therapies. Compared to tumours arising in left colon, right colorectal cancers rely on the activation of different molecular pathways (e.g. BRAF mutation and MSI status). From a clinical point of view, this results in a different response to anti-EGFR agents. Current guidelines suggest the use of cetuximab or panitumumab in RAS wild-type disease and left colon cancer especially for cytoreduction/conversion purposes, since the expected benefit in right colon cancer is absent or clinically modest. The prognostic role of microbiota in colorectal cancer disease deserves more clarification before being considered in common clinical practice. Screening policies could also be affected by these new acquisitions. At the moment, sidedness should be considered as a strong prognostic variable and a surrogate predictor of different activity of anti-EGFR agents in the metastatic setting. Its role in early stages of resected disease is still uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.